Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPF Additional presentations include preclinical and translational data reflecting the potency of buloxibutid’s upstream mechanism of action as well as the design of the upcoming Phase 2b ASPIRE trial Vicore also to […]
C21 is a potentially transformative therapy for the treatment of idiopathic pulmonary fibrosis (IPF) Vicore to receive USD 10 million upfront and is entitled to up to USD 275 million in milestones in addition to tiered royalty payments Nippon Shinyaku has been granted exclusive rights to and will be responsible for development of C21 in […]
The COMPANION pivotal study met the primary endpoint and demonstrated significantly reduced anxiety in patients with pulmonary fibrosis. AlmeeTM is the first digital therapy to address the psychological symptom burden of living with pulmonary fibrosis. Stockholm, January 4, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, […]
Development of C21 in IPF on track; final Phase 2a AIR data in first half of 2024 and Phase 2b ASPIRE initiation in first half of 2024 AlmeeTM pivotal study COMPANION completion on-track; topline results expected to be announced this month Transition to late-stage development of C21 in IPF drives increased focus in pipeline; preclinical […]
Stockholm, November 2, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drug molecules – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the third quarter 2023. Read more…
